eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Revenue of eFFECTOR Therapeutics, Inc. (EFTR)
Revenue in 2023 (TTM): $
According to eFFECTOR Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of eFFECTOR Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-22,919,000 | $-33,733,000 | $-35,811,000 | $-35,811,000 |
| 2022 | $3.55 M | $3.5 M | $-32,403,000 | $-22,665,000 | $-12,927,000 |
| 2021 | $1.43 M | $1.41 M | $-31,897,000 | $15.8 M | $15.8 M |
| 2020 | $42 M | $20.17 M | $16.06 M | $14.56 M | $14.21 M |
| 2019 | $ | $-307,000 | $-28,298,000 | $-29,739,000 | $-29,739,000 |